Article
ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
Journal of clinical laboratory analysis - 1 Jan 2012
Lu Xiaobo, Xiao Sha, Jin Cuihong, van der Straaten Tahar, Li Xiaoxia
Abstract excerpt
Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D/excision repair cross-complementing group 2 (XPD/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, and we performed a meta-analysis in order to obtain a more precise estimation for a more optimizing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
